Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects
with prostate cancer prior to it becoming commercially available. The patient will receive
bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this
therapy and safety information is provided regularly to AstraZeneca. Treatment will be
discontinued after bicalutamide 150-mg becomes commercially available.